Skip to content

Effect of Ayurvedic Metallomineral formulation on Diabetes

Pharmaceutical Standardization of Shadguna Bali Jarita Rasasindura and its efficacy on Madhumeha (Diabetes Mellitus)

Status
Active, not recruiting
Phases
Phase 2Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2012/06/002711
Enrollment
60
Registered
2012-06-04
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- non insulin dependent Diaebetics

Interventions

Intervention1: RS: 62 mg Shadaguna Balijarita Rasasindura + 188 mg , Guduchi Ghana Tablet â?? bd, orally with Madhu for 28 days Control Intervention1: GG: Guduchi Ghana 188mg + 62mg binding agent Ta

Sponsors

Institute for postgraduate teaching and research in Ayurveda
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients having Ayurvedic & modern symptomatology of Madhumeha (NIDDM) will be selected from O.P.D. and I.P.D. of I.P.G.T. & R.A., Hospital, Jamnagar. Age group of patients will be between 30 years to 70 years. Patients having FBS level >= 126 mg/dl or PPBS level >= 200 mg/dl

Exclusion criteria

Exclusion criteria: Patients of Diabetes Mellitus receiving Insulin. Patients having chronic complications of Diabetes Mellitus Micro vascular: Retinopathy, Neuropathy, & Nephropathy. Macrovascular: Coronary artery disease, Peripheral vascular disease & Cerebro-vascular disease. Other chronic debilitating diseases like STD etc.

Design outcomes

Primary

MeasureTime frame
releif in signs and symptoms of diseaseTimepoint: 28 days

Secondary

MeasureTime frame
exacerbation in signs and symptomsTimepoint: 14 days

Countries

India

Contacts

Public ContactRohit Gokarn

IPGTRA GAU

patgiri06@yahoo.co.in9429513942

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026